Every material Form 8-K Hims & Hers Health filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Hims & Hers reported third quarter 2025 revenue of $599.0 million, up 49% from a year earlier, and Adjusted EBITDA of $78.4 million, up from $51.1 million. Net income fell to $15.8 million from $75.6 million, a year-earlier figure that included a $60.8 million tax benefit. The company narrowed its full-year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million.
Q3 2025 revenue was $599.0 million, up 49% from $401.6 million; subscribers reached 2,471 thousand, up 21%.
Q3 2025 net income was $15.8 million, compared with $75.6 million in Q3 2024, which included a $60.8 million tax benefit.
Q3 2025 Adjusted EBITDA was $78.4 million, up from $51.1 million; gross margin was 74%, down from 79%.
Full-year 2025 guidance was narrowed to $2.335 billion to $2.355 billion in revenue; Q4 2025 revenue guidance is $605 million to $625 million.
Hims & Hers Health said COO Nader Kabbani will move into a new advisory role effective November 2, 2025, continuing to provide strategic guidance through July 2026. Chief Commercial Officer Mike Chi will become Chief Operating Officer on the same date, and the company will consolidate operations, marketing, product and commercial functions under him and will not have a separate Chief Commercial Officer.
Nader Kabbani determined to step into an advisory role on September 28, 2025, effective November 2, 2025, through July 2026
Mike Chi, 46, joined the company in April 2021 and will become Chief Operating Officer effective November 2, 2025
The Compensation Committee plans to review Mr. Chi's compensation in light of his expanded responsibilities; no changes have been approved
The company will not have a separate Chief Commercial Officer after the transition
Hims, Inc., a subsidiary of Hims & Hers Health, signed a 15-year lease covering about 352,012 square feet at 9885 Innovation Campus Way in New Albany, Ohio, for office, research and development, laboratory, manufacturing and pharmaceutical dispensing use. The parent company guaranteed the subsidiary's lease obligations, and the filing gives initial annual base rent of $5,984,204, so the commitment is a long-term fixed cost for shareholders.
Lease dated September 1, 2025, with an initial term of 15 years and two five-year extension options
Initial annual base rent of $5,984,204, rising about 3.25% each year; rent payments begin April 1, 2026
Base rent is abated until April 1, 2026, and partly abated at $262,838.42 per month for five months after that
A letter of credit for $5,984,204 from JPMorgan Chase Bank secures the lease, and the parent executed a guaranty
Hims & Hers reported second-quarter 2025 revenue of $544.8 million, up 73% from a year earlier, and net income of $42.5 million, compared with $13.3 million in the second quarter of 2024. The company affirmed its full-year 2025 revenue and Adjusted EBITDA guidance and gave third-quarter outlook, but free cash flow was negative $69.4 million and gross margin fell to 76% from 81%.
Q2 2025 revenue was $544.8 million, up 73% from $315.6 million; subscribers reached 2,439 thousand, up 31%
Net income was $42.5 million and Adjusted EBITDA was $82.2 million, versus $13.3 million and $39.3 million a year earlier
Free cash flow was negative $69.4 million, compared with positive $47.6 million in Q2 2024
Full-year 2025 guidance affirmed: revenue of $2.3 billion to $2.4 billion and Adjusted EBITDA of $295 million to $335 million; Q3 revenue guidance is $570 million to $590 million
Hims & Hers Health issued $1.0 billion of senior, unsecured convertible notes maturing May 15, 2030, under an indenture dated May 13, 2025. The notes carry no regular interest, and the company also entered capped call transactions costing approximately $47.8 million that are expected to reduce potential dilution from conversions.
Notes: $1.0 billion aggregate principal, maturing May 15, 2030; no regular interest accrues
Initial conversion price of approximately $70.67 per Class A share; up to 19,455,200 shares issuable on conversion at the maximum rate
Capped call cost approximately $47.8 million; cap price initially $89.95 per share, a 75.0% premium over the May 8, 2025 closing price
Notes may be redeemed from May 19, 2028 under specified conditions; the company may settle conversions in cash, shares, or both
Hims & Hers reported first quarter 2025 revenue of $586.0 million, up 111% from a year earlier, and net income of $49.5 million, compared with $11.1 million. The company affirmed its full-year 2025 revenue guidance of $2.3 billion to $2.4 billion and raised its full-year Adjusted EBITDA guidance to $295 million to $335 million. Gross margin fell to 73% from 82%, and second-quarter revenue guidance of $530 million to $550 million was below the first-quarter result.
Q1 2025 revenue was $586.0 million, up 111% year over year; net income was $49.5 million versus $11.1 million; diluted EPS was $0.20 versus $0.05.
Adjusted EBITDA was $91.1 million in Q1 2025, compared with $32.3 million a year earlier.
Full-year 2025 Adjusted EBITDA guidance was raised to $295 million to $335 million; full-year revenue guidance of $2.3 billion to $2.4 billion was affirmed.
The company set 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Hims & Hers Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →